Jaguar Health, Inc. (JAGX) - 10-Q Summary for Period Ended September 30, 2025
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for Jaguar Health, Inc., a commercial-stage pharmaceutical company focused on plant-based prescription products for human and animal health. The reporting period covers the three and nine months ended September 30, 2025. The Company operates through two segments: Human Health (primarily Mytesi and Gelclair) and Animal Health (Canalevia-CA1). The Company is classified as a non-accelerated filer and a smaller reporting company.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2024 |
|---|---|---|---|
| Total Revenue | $3,083 | $8,276 | $8,180 |
| Net Loss | $(9,648) | $(30,804) | $(29,017) |
| Net Loss Per Share (Basic & Diluted) | $(6.28) | $(22.61) | $(150.72) |
| Cash and Cash Equivalents | $3,527 | $3,527 | $13,269 |
| Total Debt (Notes Payable) | $30,756 | $30,756 | $35,541 |
| Stockholders' Equity | $4,359 | $4,359 | $13,097 |
| Accumulated Deficit | $(376,855) | $(376,855) | $(336,562) |
Material Changes vs. Prior Period
- Revenue: Total revenue for the nine months ended September 30, 2025, increased slightly by 1.2% ($96,000) compared to the prior year period. This was driven by the launch of Gelclair and increased license revenue, offset by flat Mytesi sales.
- Operating Expenses: Total operating expenses increased by 6.8% ($2.1 million) year-over-year. Sales and marketing expenses rose 39.8% due to the Gelclair launch and increased headcount. Research and development expenses decreased 11.3% following the conclusion of the Phase 3 OnTarget clinical trial.
- Net Loss: The net loss increased by 6.2% to $30.8 million for the nine-month period. This was influenced by a $1.8 million loss on the extinguishment of debt and a $4.7 million loss from changes in the fair value of financial instruments designated at Fair Value Option (FVO).
- Liquidity: Cash balances decreased significantly from $8.0 million at year-end 2024 to $3.5 million at September 30, 2025. Net cash used in operating activities was $18.2 million for the nine-month period.
Guidance, Outlook, Risks, and Unusual Items
- Going Concern: The Company has disclosed substantial doubt about its ability to continue as a going concern. Management states that current cash balances are not sufficient to fund the operating plan for the next 12 months without additional financing.
- Financing Activities: The Company raised approximately $13.9 million in financing activities during the nine months ended September 30, 2025, through ATM offerings, convertible notes, and PIPE financing. A subsequent event noted a new $10.8 million note purchase agreement with Streeterville in November 2025.
- Debt Structure: A significant portion of debt ($30.4 million) is designated at Fair Value Option (FVO), leading to volatility in earnings due to mark-to-market adjustments. The Company has complex royalty interest agreements with minimum payment obligations totaling approximately $27.0 million commencing in 2026.
- Regulatory Risks: The filing highlights risks related to potential FDA staffing disruptions and government shutdowns, which could delay product reviews. The Company is pursuing orphan drug designation and Fast Track designation for crofelemer in metastatic breast cancer patients.
- Unusual Items: The financial results were impacted by non-cash charges related to the fair value of hybrid financial instruments and losses on debt extinguishment/modification.
Key Facts for Investor Verification
- Cash Runway: Verify the sufficiency of the $3.5 million cash balance against the stated need for additional financing to fund operations for the next 12 months.
- Debt Obligations: Review the terms of the royalty interest agreements and the $27.0 million in minimum payments due starting in 2026, as these create significant future cash outflows regardless of sales volume.
- FVO Volatility: Assess the impact of the $30.4 million in FVO debt on future earnings volatility, as changes in fair value are recorded directly in the income statement.
- Revenue Concentration: Note that substantially all revenue is derived from Mytesi, with high concentration in two specialty pharmacy customers (85% of revenue in Q3 2025).
- Subsequent Financing: Confirm the terms and impact of the $10.8 million note issued to Streeterville in November 2025, which was disclosed as a subsequent event.